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INTRODUCTION
This chapter makes treatment recommendations for adults
with MCD. The cost implications for global application of
this guideline are addressed in Chapter 2.
5.1: Treatment of initial episode of adult MCD
5.1.1: We recommend that corticosteroids be given
for initial treatment of nephrotic syndrome.
(1C)
5.1.2: We suggest prednisone or prednisolone* be
given at a daily single dose of 1 mg/kg
(maximum 80 mg) or alternate-day single dose
of 2 mg/kg (maximum 120 mg). (2C)
5.1.3: We suggest the initial high dose of cortico-
steroids, if tolerated, be maintained for a mini-
mum period of 4 weeks if complete remission is
achieved, and for a maximum period of 16 weeks
if complete remission is not achieved. (2C)
5.1.4: In patients who remit, we suggest that
corticosteroids be tapered slowly over a total
period of up to 6 months after achieving
remission. (2D)
5.1.5: For patients with relative contraindications or
intolerance to high-dose corticosteroids (e.g.,
uncontrolled diabetes, psychiatric conditions,
severe osteoporosis), we suggest oral cyclo-
phosphamide or CNIs as discussed in
frequently relapsing MCD. (2D)
5.1.6: We suggest using the same initial dose and
duration of corticosteroids for infrequent
relapses as in Recommendations 5.1.2, 5.1.3,
and 5.1.4. (2D)
*Prednisone and prednisolone are equivalent, used in the same
dosage, and have both been used in RCTs depending on the country
of origin. All later references to prednisone in this chapter refer to
prednisone or prednisolone. All later references to oral cortico-
steroids refer to prednisone or prednisolone.
BACKGROUND
MCD refers to the occurrence of nephrotic syndrome with no
glomerular lesions by light microscopy (or only minimal
mesangial prominence), no staining on immunofluorescence
microscopy (or low-intensity staining for C3 and IgM), and
foot process effacement but no electron-dense deposits on
electron microscopy.121
Although spontaneous remission can occur in MCD,122–125
untreated nephrotic syndrome is associated with significant
morbidity due to accelerated atherosclerosis, in part due to
dyslipidemia,126 infections,125,127 and thromboembolic events.128
Therefore, specific treatment should be given with the goal of
achieving remission. The cornerstone of treatment has been
corticosteroids. MCD in children is exquisitely sensitive to
corticosteroids; however, adults tend to respond more slowly,
with responses occurring as late as 3–4 months after starting
therapy. The response to corticosteroids is also less predictable in
adults, as only about 75% of adults with MCD are steroid-
responsive (Table 8). Also, in contrast to children, there is a
paucity of well-designed RCTs investigating the treatment of
MCD in adults.
Although AKI is common in adults with MCD (up to
20–25%),129,130 progressive CKD is not part of the natural
history of adults with MCD, and its occurrence suggests
underlying FSGS.
More than half of adult MCD patients will experience
relapses, and up to a third of patients may become frequent
relapsers or corticosteroid-dependent.130–133 Furthermore,
a 40% relapse rate has been reported in adults who had
MCD as children,16 and these patients continue to relapse.
Secondary etiologies associated with MCD are uncommon, but
should be considered. They include Hodgkin’s disease, lithium
therapy, and nonsteroidal anti-inflammatory drugs.134
Corticosteroids are generally well-tolerated, but drug-
related adverse effects are common with prolonged/repeated
courses in SD or FR patients.
Disease Definitions
Definitions of proteinuria outcomes are as listed in Table 10,
Chapter 6. Partial remissions in proteinuria are not seen
in MCD.
RATIONALE
K There is only low-quality evidence to recommend
corticosteroids in the treatment of adult MCD. This
recommendation is based largely on extrapolation from
RCTs in children, as well as small RCTs and observational
studies in adults.
K There is only low-quality evidence to define the optimal
dose and duration of corticosteroids in adults, but a high
dose until remission is achieved followed by a slow taper
to minimize relapse is usually prescribed.
K There is very low–quality evidence suggesting that
alternate-day is equivalent to daily corticosteroids in
adult MCD.
K MCD in adults may take a longer time to remit compared
to MCD in children.
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Corticosteroids have been studied in several large pros-
pective RCTs in children99,135 and observational studies in
children and adults.129–133 In a very early multicenter
controlled study of corticosteroids compared to no treatment
in 125 nephrotic adults (including 31 MCD patients defined
by light microscopy alone), those treated with at least 20mg/
d prednisone for at least 6 months showed an early and rapid
decrease in proteinuria compared to the control group.
However, by two and a half years, there was no difference in
proteinuria or serum albumin in the two groups.123 Similarly,
in one small RCT of 28 adult MCD patients that compared
prednisone 125mg every other day for 2 months with
placebo, there was no difference in overall remission rates
over 77 months follow-up, although a significant percentage
of the placebo arm ended up being treated with prednisone
over this time frame. However, patients treated with
prednisone went into remission more rapidly; 12 of 14
treated patients were in complete remission before 2 months,
compared to 6 of 14 controls.124,136
Although there are no controlled trials comparing daily vs.
alternate-day corticosteroids in adults, observational studies
have not shown any difference in response rates.130 Corti-
costeroid therapy leads to complete remission in over 80% of
adults with MCD. The time course to a complete remission is
delayed compared to children, with 50% responding by 4
weeks but the remaining 10–25% requiring 12–16 weeks of
therapy.129,130 It is known that, in children, 6 months of
corticosteroid treatment is associated with a lower relapse
rate than 3 months of therapy.135 The optimal method to
taper corticosteroids in adults is not known, but cortico-
steroids are commonly tapered by 5–10mg/wk or less after
achieving remission, for a total period of corticosteroid
exposure of at least 24 weeks.125,129,130
Only a few patients have been treated at the time of
initial presentation with steroid-free regimens (e.g., cyclo-
phosphamide132,137,138 or cyclosporine139). In this very
limited experience, the typical response rate of 75% is
comparable to corticosteroids.
For infrequent relapses, repeat courses of corticosteroids
may be used as in the first episode of MCD. There are no
RCTs to guide the therapy of relapse in adult MCD.
Reinstitution of prednisone usually results in a remission.
5.2: FR/SD MCD
5.2.1: We suggest oral cyclophosphamide 2–2.5 mg/kg/
d for 8 weeks. (2C)
5.2.2: We suggest CNI (cyclosporine 3–5 mg/kg/d or
tacrolimus 0.05-0.1 mg/kg/d in divided doses)
for 1–2 years for FR/SD MCD patients who
have relapsed despite cyclophosphamide, or for
people who wish to preserve their fertility. (2C)
5.2.3: We suggest MMF 500–1000 mg twice daily for
1–2 years for patients who are intolerant of
corticosteroids, cyclophosphamide, and CNIs.
(2D)
RATIONALE
K There is low-quality evidence to suggest the value of
alkylating agents in adult FR/SD MCD. Support for this
approach comes from RCTs in children, and observa-
tional studies in adults.
K There is low-quality evidence to suggest that CNIs can
induce complete or partial remission in adult MCD, but
relapse rates may be higher than with alkylating agents
after cessation of CNIs.
K There is very low–quality evidence to suggest the use of
MMF as a corticosteroid or CNI-sparing agent.
In observational studies, treatment with cyclophos-
phamide leads to remission in a significant number of
adults.129,130,132 The relapse-free interval appears to be longer
than with cyclosporine (see below). In an observational study,
the initial response rates with cyclophosphamide in SD adults
appeared excellent (all nine patients were able to be weaned
off steroids in one study);129 however, five of these patients
relapsed. In this study FR MCD patients appeared to fare
better than SD MCD, with 80% of patients showing sustained
remission at a mean follow-up of 9.1 years. Similarly, SD
children may be less responsive to cyclophosphamide than
frequent relapsers.43 In another study, 21 of 36 adults with
FR/SD MCD attained remission within 8 weeks and four
more patients (total of 25/31 or 69%) within 16 weeks. The
addition of prednisone to cyclophosphamide did not appear
to provide added benefit. Remissions appeared to be more
durable with cyclophosphamide compared to steroids.132
In another study, 55% of 20 patients treated with cyclo-
phosphamide (for FR or SD MCD) had a complete or partial
remission.130 There is one report of the effectiveness of
regimens using i.v. cyclophosphamide in adults.140
Table 8 | Dosage regimens in MCD
Drug and dosing scheme
Initial treatment
Prednisone
Daily single dose of 1mg/kg (maximum 80mg) or alternate-day single
dose of 2mg/kg (maximum 120mg)
–until complete remission (minimum 4 weeks to a maximum of
16 weeks)
–after complete remission, tapered slowly over 6 months
FR or SD MCD
1. Cyclophosphamide (oral) single course
2–2.5mg/kg/d as tolerated for 8 weeks
2. Relapsed despite cyclophosphamide, or patients of childbearing age
a. Cyclosporine starting dose 3–5mg/kg/d (in two equally divided
doses)
b. Tacrolimus 0.05–0.1mg/kg/d (in two equally divided doses)
Following 3 months of stable remission, tapered to reach the
minimum dosage that maintains remission, for 1–2 years
3. Intolerant to corticosteroids, cyclophosphamide, and/or CNIs
a. Mycophenolate mofetil 500–1000mg twice daily for 1–2 years
FR, frequently relapsing; MCD, minimal-change disease; SD, steroid-dependent.
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Many observational studies have reported the efficacy of
cyclosporine with remission rates of 70-90%.130,141 In an
RCT of 73 adults and children with FR/SD nephrotic
syndrome (31 with MCD; 42 with FSGS), treatment was
given with either cyclophosphamide (2.5mg/kg/d) for 8
weeks or cyclosporine (5mg/kg/d) for 9 months, followed by
a 3-month taper to withdrawal. At 9 months, remission rate
did not differ significantly: 64% (18/28) of patients on
cyclophosphamide and 74% (26/35) of patients on cyclo-
sporine maintained remission. However, at 2 years, 25% of
patients assigned to cyclosporine vs. 63% of patients assigned
to cyclophosphamide were still in remission.62 Another RCT
of 52 patients noted that remission was achieved sooner in
patients treated with cyclosporine plus 0.8mg/kg/d predni-
sone compared to patients receiving only 1mg/kg/d pre-
dnisone, suggesting an additional benefit of lower exposure
to corticosteroids (Online Suppl Tables 20, 21).142
The optimal dose and duration of cyclosporine therapy is
unknown. In an RCT of adults and children with FR/SD
nephrotic syndrome, cyclosporine was dosed at 5mg/kg/d
for 9 months followed by a taper over 3 months.62 The
possibility of cyclosporine dependency is high when treatment
is abruptly stopped after achieving complete remission.
However, prolonged treatment in 36 adult patients for a mean
of 26 months, followed by slow withdrawal, led to sustained
remissions without steroids in 11 of 14 patients and with low
doses of corticosteroids in three patients. In 20% of patients,
who remained cyclosporine-dependent, doses of o3mg/kg/d
were sufficient to maintain remission. The cumulative rate of
remissions appears to reach a plateau by 6 months.143,144
Tacrolimus, administered for 24 weeks was compared to
i.v. cyclophosphamide in a small RCT in SD patients with
achieved response rates similar to cyclosporine. All patients
in this study were able to discontinue corticosteroids.140
There are insufficient data to suggest a therapeutic level
for CNI in adult MCD patients. After starting the drug with
the suggested dosing regimen in Table 8 and achieving
remission, the CNI dose should be progressively reduced to
the lowest level that will maintain the remission. Many
patients will be able to come off corticosteroids completely140
and every effort should be made to reduce and stop
corticosteroids after starting CNI.
In children with MCD, MMF has been used as a steroid-
sparing agent (see Recommendation 3.3.5). The experience
with MMF in adults has been limited to case reports.145–147
5.3: Corticosteroid-resistant MCD
5.3.1: Re-evalulate patients who are corticosteroid-
resistant for other causes of nephrotic syn-
drome. (Not Graded)
RATIONALE
K Corticosteroid-resistant MCD suggests FSGS.
An estimated 10% of adult MCD patients are steroid-resistant
(failed 16 weeks of daily or alternate-day corticosteroids as
outlined previously). Steroid resistance may be due to
undetected FSGS (which may not be seen in a biopsy specimen
because it is a focal lesion). A repeat biopsy could be considered
and may show FSGS, which is associated with a worse prognosis
than MCD. There are no RCTs and very few observational data
on treatment strategies of steroid-resistant MCD in adults.
Treatment strategy as outlined in Chapter 6 is suggested.
5.4: Supportive therapy
5.4.1: We suggest that MCD patients who have AKI
be treated with renal replacement therapy as
indicated, but together with corticosteroids, as
for a first episode of MCD. (2D)
5.4.2: We suggest that, for the initial episode of
nephrotic syndrome associated with MCD,
statins not be used to treat hyperlipidemia,
and ACE-I or ARBs not be used in normo-
tensive patients to lower proteinuria. (2D)
RATIONALE
K AKI may accompany MCD in adults. This is usually
reversible with continued steroid therapy. Supportive
care, including renal replacement therapy, may be
temporarily required. Proteinuria in adult MCD will
typically remit with corticosteroids. As a consequence,
the accompanying hyperlipidemia will remit with resolu-
tion of proteinuria, negating the need for statin therapy.
K Proteinuria in adult MCD will typically remit with cortico-
steroids, and statins and RAS blockade to help reduce
proteinuria are not necessary if early remission is achieved.
AKI, sometimes severe enough to require dialysis, can
occur in patients with MCD. Risk factors include older age,
hypertension, severe nephrotic syndrome, and underlying
arteriosclerosis of the kidney.130,148 Kidney function typically
recovers even in the most severely affected patients, although
patients who have experienced kidney failure may have
residual chronic renal impairment.130 Careful attention to
volume status, as well as continued therapy with cortico-
steroids, and other supportive therapy for AKI are suggested.
There is only one small study of 40 adults who had relapsing
nephrotic syndrome as children. This study did not show a
higher incidence of cardiovascular disease, implying that long-
term cardiovascular risk was not increased by intermittent
hyperlipidemia during nephrotic relapses in childhood.149 The
use of antihyperlipidemic agents and ACE-I or ARBs may be
considered on a case-by-case basis in FR/SD MCD adults in
whom rapid remission is not achieved. It is important to note
that adding an ACE-I or ARB in a severely nephrotic patient
who is being aggressively diuresed may precipitate AKI.150
Economic Considerations
Prednisone and cyclophosphamide are less costly than CNIs
and MMF. Cost factors need to be considered in patients who
are not able to afford or access the more expensive medi-
cations.151 The addition of ketoconazole is safe and can lead
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to significant reduction in costs associated with CNIs, but
drug levels need to be assessed to avoid nephrotoxicity.73
RESEARCH RECOMMENDATIONS
K RCTs should investigate the use of CNIs or MMF as
alternatives to corticosteroids for the first episode of
adult MCD.
K RCTs are needed to compare CNIs to cyclophosphamide
in FR/SD MCD, and to establish if cyclosporine or
tacrolimus should be the preferred CNI.
K RCTs are needed to study the role of rituximab in FR/SD
MCD.
K RCTs are needed to study the role of levamisole in FR/SD
MCD.
K Evidence should be collected in these RCTs to evaluate
the long-term cardiovascular, metabolic, infectious, and
bone risk of FR/SD MCD, and corresponding treatment.
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